ArticleArchives of endocrinology and metabolism2025
The combined detection of aspiration biopsy, computed tomography and BRAFV600E gene has high diagnostic value for papillary thyroid carcinoma.
Article in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated the clinical value of ultrasound-guided fine-needle aspiration biopsy (US-FNAB), computed tomography (CT) and BRAFV600E combination for papillary thyroid carcinoma (PTC) diagnosis. SUBJECTS AND
methodsA total of 300 patients with thyroid nodules were assigned to the PTC group (n = 184) and the nodular goiter (NG) group (n = 116). The positive detection rates of US-FNAB, CT and BRAFV600E gene mutation and their relationship with tumor number, tumor diameter, lymphatic metastasis, capsule invasion and tumor-node-metastasis (TNM) staging were analyzed, with their diagnostic value for PTC analyzed by the receiver operating characteristic (ROC) curve. The area under multiple ROC curves (AUCs) were compared using MEDCALC software.
resultsThe positive detection rates of US-FNAB, CT and BRAFV600E gene mutation were 78.80%, 72.28% and 83.15% in the PTC group, and 30.17%, 27.59% and 9.48% in the NG group, while the negative detection rates were 21.20%, 27.72% and 16.85% in the PTC group, and 69.82%, 72.41% and 90.52% in the NG group. Positive US-FNAB and BRAFV600E gene mutation in PTC patients related to TNM staging. Positive CT and BRAFV600E gene mutation linked to lymphatic metastasis. US-FNAB (AUC: 0.743, sensitivity: 78.80%, specificity: 69.83%), CT (AUC: 0.723, sensitivity: 77.28%, specificity: 72.41%) and BRAFV600E (AUC: 0.868, sensitivity: 83.15%, specificity: 90.52%) gene detections helped PTC diagnosis, with their combined diagnostic value (AUC: 0.938, sensitivity: 78.26%, specificity: 96.55%) surpassing that of them alone.
conclusionUS-FNAB, CT and BRAFV600E gene tests helped PTC diagnosis, and their combined detection had higher diagnostic value for PTC than their single detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.